Cadent Therapeutics focuses on developing innovative therapies for neuropsychiatric disorders, particularly targeting conditions such as schizophrenia and treatment-resistant depression. The company has advanced two clinical-stage programs, including CAD-9303, which aims to address the negative and cognitive symptoms of schizophrenia by modulating NMDA receptor activity. This approach is based on evidence suggesting that these receptors function sub-optimally in individuals with schizophrenia, potentially offering a new avenue for treatment. Additionally, Cadent's MIJ821, which selectively modulates a subset of NMDA receptors, is being explored as a therapy for patients who do not respond to existing depression treatments.

The acquisition of Cadent by Novartis enhances their neuroscience portfolio and reflects a commitment to addressing significant unmet needs in neuropsychiatric care. Alongside CAD-9303 and MIJ821, Cadent is also developing CAD-1883, a Phase II asset for movement disorders. This strategic move underscores the importance of innovative research in creating transformative therapies for patients suffering from chronic neuropsychiatric illnesses, aiming to improve their quality of life and overall functioning in society.

United States

Cadent Therapeutics is rapidly advancing apipelineof novel allosteric modulators of ion channels – taking a well-established pharmaceutical approach and stepping out into new territory.SK channels and NMDA receptors are ion channels that are critical formodulating the strength, timing, and integration ofcommunication betweenand within neurons and neuronal networksin the central nervous system.

Cadent Therapeutics

Company Details